A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 3,300 shares of PBYI stock, worth $8,580. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,300
Previous 105,500 96.87%
Holding current value
$8,580
Previous $559,000 98.21%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.92 - $5.83 $33,962 - $67,808
11,631 New
11,631 $37,000
Q4 2023

Feb 14, 2024

SELL
$2.23 - $4.49 $130,046 - $261,843
-58,317 Reduced 32.38%
121,796 $527,000
Q3 2023

Nov 14, 2023

SELL
$2.63 - $4.09 $103,419 - $160,831
-39,323 Reduced 17.92%
180,113 $473,000
Q2 2023

Aug 14, 2023

SELL
$2.6 - $3.58 $44,041 - $60,641
-16,939 Reduced 7.17%
219,436 $774,000
Q1 2023

May 15, 2023

BUY
$2.21 - $4.82 $189,657 - $413,642
85,818 Added 57.0%
236,375 $730,000
Q4 2022

Feb 14, 2023

SELL
$2.12 - $5.08 $125,944 - $301,792
-59,408 Reduced 28.29%
150,557 $636,000
Q3 2022

Nov 14, 2022

SELL
$2.27 - $3.84 $203,192 - $343,726
-89,512 Reduced 29.89%
209,965 $497,000
Q2 2022

Aug 15, 2022

BUY
$1.64 - $3.3 $356,285 - $716,915
217,247 Added 264.19%
299,477 $853,000
Q1 2022

May 16, 2022

SELL
$2.13 - $3.24 $783 - $1,192
-368 Reduced 0.45%
82,230 $237,000
Q4 2021

Feb 14, 2022

SELL
$2.85 - $6.58 $334,333 - $771,899
-117,310 Reduced 58.68%
82,598 $251,000
Q3 2021

Nov 15, 2021

BUY
$6.63 - $9.39 $20,354 - $28,827
3,070 Added 1.56%
199,908 $1.4 Million
Q2 2021

Aug 16, 2021

BUY
$8.98 - $11.6 $108,029 - $139,548
12,030 Added 6.51%
196,838 $1.81 Million
Q1 2021

May 17, 2021

SELL
$9.38 - $13.63 $317,569 - $461,457
-33,856 Reduced 15.48%
184,808 $1.8 Million
Q4 2020

Feb 16, 2021

SELL
$7.78 - $12.13 $1.52 Million - $2.37 Million
-195,007 Reduced 47.14%
218,664 $2.24 Million
Q3 2020

Nov 16, 2020

BUY
$9.5 - $11.14 $3.01 Million - $3.53 Million
317,066 Added 328.21%
413,671 $4.17 Million
Q2 2020

Aug 14, 2020

SELL
$7.01 - $13.24 $1.03 Million - $1.95 Million
-147,463 Reduced 60.42%
96,605 $1.01 Million
Q1 2020

May 15, 2020

SELL
$6.28 - $14.57 $1.88 Million - $4.36 Million
-299,008 Reduced 55.06%
244,068 $2.06 Million
Q4 2019

Feb 14, 2020

BUY
$6.5 - $10.73 $549,744 - $907,500
84,576 Added 18.45%
543,076 $4.75 Million
Q3 2019

Nov 14, 2019

SELL
$8.75 - $12.85 $5.85 Million - $8.59 Million
-668,343 Reduced 59.31%
458,500 $4.94 Million
Q2 2019

Aug 14, 2019

BUY
$12.3 - $35.76 $7.75 Million - $22.5 Million
630,126 Added 126.86%
1,126,843 $14.3 Million
Q1 2019

May 15, 2019

BUY
$20.77 - $42.37 $3.81 Million - $7.78 Million
183,600 Added 58.64%
496,717 $0
Q4 2018

Feb 14, 2019

SELL
$20.07 - $46.7 $16.3 Million - $37.9 Million
-811,314 Reduced 72.15%
313,117 $6.37 Million
Q3 2018

Nov 13, 2018

BUY
$41.2 - $59.85 $13 Million - $18.9 Million
316,423 Added 39.16%
1,124,431 $0
Q2 2018

Aug 10, 2018

BUY
$48.3 - $68.25 $38.3 Million - $54.2 Million
793,652 Added 5528.36%
808,008 $0
Q1 2018

May 11, 2018

SELL
$59.7 - $99.25 $49.1 Million - $81.6 Million
-822,569 Reduced 98.28%
14,356 $977,000
Q4 2017

Feb 09, 2018

SELL
$93.85 - $132.45 $19.6 Million - $27.7 Million
-209,155 Reduced 19.99%
836,925 $82.7 Million
Q3 2017

Nov 09, 2017

BUY
$72.0 - $119.75 $75.3 Million - $125 Million
1,046,080
1,046,080 $125 Million

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $118M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.